12
Sep

Partners Biogen Idec and AbbVie are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.

…read more

Source: AbbVie and Biogen inch toward the FDA with once-a-month MS drug

    

0 No comments